Can a wearable device improve dialysis? small study hopes to find out

NCT ID NCT07217041

Completed Knowledge-focused Sponsor: HemoCept Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a device called HemoCept in 12 adults with end-stage kidney disease on dialysis. The goal was to see if the device could accurately track changes in hydration during fluid removal. Researchers compared device readings to changes in dry weight before, during, and after dialysis. The study is complete, but results are not yet available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HemoCept device
What this could lead to: If successful, this could lead to a non-invasive way to monitor hydration in dialysis patients, potentially improving treatment precision.
What could go wrong: This is a very small pilot study with only 12 participants, so results may not apply to everyone. The device's accuracy is still unproven, and there may be device-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESRD (END STAGE RENAL DISEASE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic renal failure syndrome end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESRD (END STAGE RENAL DISEASE)

Contacts and locations

Locations

Sierra Nevad Specialty Care

Reno, Nevada, 89511, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.